Abeona Therapeutics Q3 profit beats analyst expectations

Overview

• Abeona Q3 net income and EPS beat analyst expectations

• Company’s cash position at $207.5 mln, sufficient for over two years of operations

Outlook

• Company anticipates ZEVASKYN patient treatments to start in 4Q 2025

• Abeona sees strong patient demand and expanding treatment site network

Result Drivers

• PATIENT DEMAND – Abeona reports strong and growing patient demand for ZEVASKYN despite treatment delay

• TREATMENT CENTER EXPANSION – Strategic expansion of QTC network with three activated centers and more onboarding

• MARKET ACCESS – Broad market access with commercial payer coverage and CMS J-code for ZEVASKYN

Key Details

Analyst Coverage

• The current average analyst rating on the shares is “strong buy” and the breakdown of recommendations is 6 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”

• The average consensus recommendation for the pharmaceuticals peer group is “buy.”

• Wall Street’s median 12-month price target for Abeona Therapeutics Inc is $20.00, about 79.1% above its November 11 closing price of $4.17

Press Release:

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.